GlassScriptPhysician profile
Charles W Duckworth
NPI 1033199989
$8,705.83
in general payments reported to CMS, 2019-2025
35 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $437 · 2021: $780 · 2022: $1,508 · 2023: $1,341 · 2024: $1,808 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,738.20 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $869.61 | 2019-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $429.74 | 2019-2025 | Entyvio |
| Pfizer INC. | $392.60 | 2019-2025 | |
| Qol Medical, LLC | $364.09 | 2022-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $322.18 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $317.39 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.25 | 2019-2024 | Trulance |
| Genzyme Corporation | $235.54 | 2023-2025 | |
| Organon LLC | $165.95 | 2023-2025 | Ontruzant, Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $155.51 | 2019-2025 | Rebyota, Clenpiq |
| Enterra Medical, INC. | $153.83 | 2024-2025 | |
| Boston Scientific Corporation | $142.88 | 2019-2023 | |
| Celgene Corporation | $136.38 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $111.53 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $98.69 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $96.19 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $88.94 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $86.45 | 2025 | Rezdiffra |
| Allergan, INC. | $77.77 | 2019-2020 | |
| Ambu INC. | $61.99 | 2020 | |
| Endogastric Solutions, INC | $49.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $39.38 | 2024-2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $39.18 | 2025 | Dupixent |
| Ardelyx, INC. | $38.42 | 2025 | Ibsrela |
| Ucb, INC. | $33.69 | 2019 | |
| Intercept Pharmaceuticals, INC. | $29.57 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $23.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.04 | 2025 | Givlaari |
| Braintree Laboratories, INC. | $18.41 | 2022 | |
| Amgen INC. | $17.85 | 2023 | Avsola, Amjevita |
| Alexion Pharmaceuticals, INC. | $15.36 | 2019 | |
| Novo Nordisk INC | $14.28 | 2025 | Wegovy |
| Shionogi INC | $11.60 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Duckworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.